Jianxin Huo

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 8

Top Venues

Antibodies (Basel, Switzerland)

Science translational medicine

Vaccines

FEBS letters

Bioprocessing Technology Institute, Agency for Science Technology and Research

National University of Singapore (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Bioprocessing Technology Institute, Agency for Science Technology and Research Apr 01 2020

Singapore

Senior Staff Scientist :: Immunology Group

Education History

National University of Singapore May 28 1998 - Sep 30 2003

Singapore

PHD :: National University Medical Institutes

Nankai University Aug 28 1987 - Jul 17 1991

China

BSC :: Biology

Publications

Shi Yong Neo, Le Tong, Joni Chong, Yaxuan Liu, Xu Jing, Mariana M S Oliveira, Yi Chen, Ziqing Chen, Keene Lee, Nutsa Burduli, Xinsong Chen, Juan Gao, Ran Ma, Jia Pei Lim, Jianxin Huo, Shengli Xu, Evren Alici, Stina Linnea Wickström, Felix Haglund, Johan Hartman, Arnika Kathleen Wagner, Yihai Cao, Rolf Kiessling, Kong Peng Lam, Lisa S Westerberg, Andreas Lundqvist
Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis. Science translational medicine 16 (747) (2024)
Shi Yong Neo, Le Tong, Joni Chong, Yaxuan Liu, Xu Jing, Mariana M S Oliveira, Yi Chen, Ziqing Chen, Keene Lee, Nutsa Burduli, Xinsong Chen, Juan Gao, Ran Ma, Jia Pei Lim, Jianxin Huo, Shengli Xu, Evren Alici, Stina Linnea Wickström, Felix Haglund, Johan Hartman, Arnika Kathleen Wagner, Yihai Cao, Rolf Kiessling, Kong Peng Lam, Lisa S Westerberg, Andreas Lundqvist
Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis. Science translational medicine 16 (747) (2024)
Yuxing Li, Gui-Xin Ruan, Wenjing Chen, Hengjun Huang, Rui Zhang, Jing Wang, Yu Ouyang, Zhijian Zhu, Limin Meng, Ruisi Wang, Jianxin Huo, Shengli Xu, Xijun Ou
The histone H2B ubiquitination regulator Wac is essential for plasma cell differentiation. FEBS letters (2023)
Chin Shern Lau, May Lin Helen Oh, Soon Kieng Phua, Ya Li Liang, Yanfeng Li, Jianxin Huo, Yuhan Huang, Biyan Zhang, Shengli Xu, Tar-Choon Aw
Kinetics of the Neutralizing and Spike SARS-CoV-2 Antibodies following the Sinovac Inactivated Virus Vaccine Compared to the Pfizer mRNA Vaccine in Singapore. Antibodies (Basel, Switzerland) 11 (2) (2022)
Jianxin Huo, Yuhan Huang, Ziying Zheng, Xin Ni Tay, Farouq Bin Mahfut, Wei Zhang, Kong-Peng Lam, Steven C L Ho, Shengli Xu
Development of a T cell-redirecting bispecific antibody targeting B-cell maturation antigen for the suppression of multiple myeloma cell growth. Antibody therapeutics 5 (2) (2022)
Chin Shern Lau, John Thundyil, May Lin Helen Oh, Soon Kieng Phua, Ya Li Liang, Yanfeng Li, Jianxin Huo, Yuhan Huang, Biyan Zhang, Shengli Xu, Tar-Choon Aw
Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster. Antibodies (Basel, Switzerland) 11 (4) (2022)
Biyan Zhang, Jianxin Huo, Yuhan Huang, Shuan Yong Teo, Kaibo Duan, Yanfeng Li, Lim Kai Toh, Kong Peng Lam, Shengli Xu
mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines. Vaccines 10 (7) (2022)
Jianxin Huo, Shengli Xu, Kong-Peng Lam
FAIM: An Antagonist of Fas-Killing and Beyond. Cells 8 (6) (2019)

Jianxin Huo.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Jianxin Huo